Abbvie Inc.

Abb Vie Deutschland Gmbh & Co. Kg

Abbott Biotechnology Ltd.

Abbott Laboratories Corporation

Abbott Gmbh & Co Kg

Basf Aktiengesellschaft

Abbvie Biotechnology Ltd

Abbvie Deutschland Gmbh and Co Kg

Boris Labkovsky

Jochen G Salfeld

Michael White

Zehra Kaymakcalan

Paul Sakorafas

John A Mankovich

Tristan J Vaughan

Heinz Hillen

Brian Timothy McGuinness

Ulrich Ebert

Stefan Barghorn

David Schoenhaut

Deborah J Allen

Andrew J Roberts

Alison Jane Wilton

Andreas R Striebinger

Patrick Keller

Hendricus R J M Hoogenboom

Michael Roguska

Alexander Robert Duncan

Geertruida Machteld Veldman

Nicholas W Warne

Subhashis Banerjee

Angela Widom

Thor Las Holtet

Elaine Joy Derbyshire

Daniel Edward Tracey

John Gawain Elvin

Sara Carmen

Michael Paskind

Stephen Smith

Sarah Leila Du Fou

Stuart Friedrich

Amy Venturini

Angela Myles

Tariq Ghayur

Larry L Green

Xiao-Chi Jia

Jaspal Singh Kang

John Stephen Babcook

Jeffrey W Voss

Angela Kantor

James Wieler

Brad Hedberg

Brian T Mcguinness

Richard W Dixon

Edward T Olejniczak

John E Harlan

Ana Pereda-Lopez

Hendricus Renerus Hoogenboom

Thomas F Holzman

Georgeen Gaza-Bulseco

Pratibha Mishra

Subramanya Hegde

Sudha Krishnan

Hendricus Rjm Hoogenboom

Rohinton P Edalji

Liping Yu

Tariq Ghayer

Simon Mark Brocklehurst

Celia Patricia Shorrock

Julia Elizabeth Thompson

Simon Nicholas Lennard

Alison J Wilton

Hendricus R Hoogenboom

Hendricus RJM Hoogenboom

Brian T Mcguiness

Anti-A&#x3b2; globulomer antibodies, antigen-binding moieties thereof, corresponding hybridomas, nucleic acids, vectors, host cells, methods of producing said antibodies, compositions comprising said antibodies, uses of said antibodies and methods of using said antibodies. The present invention relates to anti-A&#x3b2; globulomer antibodies having a binding affinity to A&#x3b2;(20-42) globulomer that is greater than the binding affinity of the antibody to A&#x3b2;(1-42) globulomer, antigen-binding moieties thereof, hybridomas producing said antibodies, nucleic acids encoding said antibodies, vectors comprising said nucleic acids, host cells comprising said vectors, methods of producing said antibodies, compositions comprising said antibodies, therapeutic and diagnostic uses of said antibodies and corresponding methods relating to Alzheimer's disease and other amyloidoses.

Anti-A&#x3b2; globulomer 4D10 antibodies

The subject invention relates to monoclonal antibodies (e.g., 8F5 and 8C5) that may be used, for example, in the prevention, treatment and diagnosis of Alzheimer's Disease or other neurodegenerative disorders.

Monoclonal antibodies against amyloid beta protein and uses thereof

The subject invention relates to monoclonal antibodies that may be used in the treatment and diagnosis of Alzheimer's Disease. In particular, the present invention relates to monoclonal antibodies referred to as 10F4 and 3C5 and to other monoclonal antibodies (e.g., murine, human or humanized) having similar properties thereto.

A&#x3b2; conformer selective anti-A&#x3b2; globulomer monoclonal antibodies

Provided are glycoengineered populations of Fc domain-containing binding proteins with a reduced anti-drug immune response (ADA). Also provided are methods of treating disease using such compositions, and methods and host for making such compositions.

Glycoengineered binding protein compositions

Anti-A&#x3b2; globulomer 7C6 antibodies

Abeta conformer selective anti-Abeta globulomer monoclonal antibodies

Human antibodies, preferably recombinant human antibodies, that specifically bind to human interleukin-12 (hIL-12) are disclosed. Preferred antibodies have high affinity for hIL-12 and neutralize hIL-12 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, of the invention are useful for detecting hIL-12 and for inhibiting hIL-12 activity, e.g., in a human subject suffering from a disorder in which hIL-12 activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies of the invention, and methods of synthesizing the recombinant human antibodies, are also encompassed by the invention.

Human antibodies that bind the P40 subunit of human IL-12 and methods for using the same

Methods of treatment using human antibodies that bind IL-12

Human antibodies that bind human interleukin-12

Human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor &#x3b1; (hTNF&#x3b1;) are disclosed. These antibodies have high affinity for hTNF&#x3b1; (e.g., K=10M or less), a slow off rate for hTNF&#x3b1; dissociation (e.g., K=10secor less) and neutralize hTNF&#x3b1; activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, of the invention are useful for detecting hTNF&#x3b1; and for inhibiting hTNF&#x3b1; activity, e.g., in a human subject suffering from a disorder in which hTNF&#x3b1; activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies of the invention, and methods of synthesizing the recombinant human antibodies, are also encompassed by the invention.

Human antibodies that bind human TNF&#x3b1;

Anti-A&#x3b2; globulomer 5F7 antibodies

Amyloid-beta globulomer antibodies

Growing community of inventors

Wales, MA, United States of America

Boris Labkovsky